Acacb knock-out mice [2], [3], [4] and rats treated with Acaca or Acacb anti-sense nucleotide inhibitors [12] suggested a potential therapeutic target for ACACB in insulin resistance, obesity, metabolic syndrome, and type 2 diabetes. The gene discussed is ACACB; the disease is metabolic syndrome.